The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000878370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/07/2026
Date registered
Help: Date registered
17/07/2026
Date last updated
Help: Date last updated
29/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Selective shoulder nerve blocks versus superior trunk block for pain relief in patients undergoing shoulder arthroscopy: a randomised feasibility trial
Scientific title
Suprascapular, Axillary and Lateral Pectoral Nerve Blocks (SAXIPec) Versus Superior Trunk Block for Shoulder Arthroscopy: A Randomised Feasibility Trial Evaluating Patient-Reported Outcomes
Additional trial identifiers [1] 317787 0
Nil
Universal Trial Number (UTN)
Trial acronym
SAXIPec
Related trial records

Health condition
Health condition(s) studied:
Postoperative pain following shoulder arthroscopy 342697 0
Condition category
Condition code
Anaesthesiology 338836 338836 0 0
Pain management
Musculoskeletal 338936 338936 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Arm 1:
Participants undergoing elective unilateral shoulder arthroscopy will receive the allocated ultrasound-guided regional anaesthesia immediately before induction of general anaesthesia in the anaesthetic bay. All nerve blocks will be performed by consultant anaesthetists experienced in ultrasound-guided regional anaesthesia using a sterile technique in keeping with ANZCA guidelines, and single-use 80mm needles with ropivacaine 0.5% administered by syringe under real-time ultrasound guidance.

SAXIPec group: ultrasound-guided posterior suprascapular nerve block (10 mL 0.5% ropivacaine), trans-quadrangular space axillary nerve block (7 mL 0.5% ropivacaine), and lateral pectoral nerve block (3 mL 0.5% ropivacaine).

General anaesthesia will then be induced immediately after completion of the regional block. Surgery will proceed according to routine practice. General anaesthesia will otherwise be at the discretion of the treating anaesthetist, while postoperative multimodal analgesia will be standardised according to institutional protocol.

Intervention fidelity will be assessed using study-specific REDCap electronic data collection forms completed by the treating anaesthetist performing the nerve block(s). The forms document completion of the allocated intervention, local anaesthetic volumes administered, and any protocol deviations or crossover. Access to the REDCap database is restricted to authorised study investigators.
Intervention code [1] 334630 0
Treatment: Drugs
Intervention code [2] 334717 0
Treatment: Surgery
Description of the comparator or control
Arm 2 (Comparator): Superior trunk block.Participants undergoing elective unilateral shoulder arthroscopy will receive the allocated ultrasound-guided regional anaesthesia immediately before induction of general anaesthesia in the anaesthetic bay. All nerve blocks will be performed by consultant anaesthetists experienced in ultrasound-guided regional anaesthesia using a sterile technique in keeping with ANZCA guidelines, and single-use 80mm needles with ropivacaine 0.5% administered by syringe under real-time ultrasound guidance.

Superior trunk group: Ultrasound-guided superior trunk block (15 mL 0.5% ropivacaine).

General anaesthesia will then be induced immediately after completion of the regional block. Surgery will proceed according to routine practice. General anaesthesia will otherwise be at the discretion of the treating anaesthetist, while postoperative multimodal analgesia will be standardised according to institutional protocol.
Intervention fidelity will be assessed using study-specific REDCap electronic data collection forms completed by the treating anaesthetist performing the nerve block(s). The forms document completion of the allocated intervention, local anaesthetic volumes administered, and any protocol deviations or crossover. Access to the REDCap database is restricted to authorised study investigators.
Control group
Active

Outcomes
Primary outcome [1] 346043 0
Recruitment feasibility
Timepoint [1] 346043 0
Assessed weekly using study recruitment logs throughout the recruitment period.
Primary outcome [2] 346044 0
Successful delivery of the allocated intervention
Timepoint [2] 346044 0
Immediately following completion of the allocated nerve block(s), on the day of surgery.
Primary outcome [3] 346045 0
Completeness of patient-reported outcome collection (Quality of Recovery-15 [QoR-15] questionnaire).
Timepoint [3] 346045 0
Baseline (preoperatively), and 24, 48 and 72 hours after surgery. The primary feasibility assessment will be based on questionnaire completion at 72 hours after surgery.
Secondary outcome [1] 464421 0
Pain intensity at rest
Timepoint [1] 464421 0
Baseline assessments will be performed before randomisation by a study investigator.. Pain assessments 30 minutes after nerve block placement, upon arousal in the Post-Anaesthesia Care Unit, and at 12 and 24 hours postoperatively will be performed by a blinded outcome assessor. Assessments will be conducted in person while the participant remains in hospital and by telehealth after discharge.
Secondary outcome [2] 464422 0
Phrenic nerve paresis
Timepoint [2] 464422 0
Before block placement and 30 minutes after block placement
Secondary outcome [3] 464423 0
Opioid consumption
Timepoint [3] 464423 0
First 24 postoperative hours
Secondary outcome [4] 464424 0
Quality of Recovery-15 total score
Timepoint [4] 464424 0
Preoperative baseline and 24, 48 and 72 hours after surgery. Assessments will be conducted in person while the participant remains in hospital and by telehealth after discharge. Post operative scores will be entered into study-specific REDCap forms by the blinded assessor.
Secondary outcome [5] 464857 0
Pain during shoulder specific movements
Timepoint [5] 464857 0
Baseline assessments will be performed before randomisation by a study investigator.. Pain assessments 30 minutes after nerve block placement, upon arousal in the Post-Anaesthesia Care Unit, and at 12 and 24 hours postoperatively will be performed by a blinded outcome assessor. Assessments will be conducted in person while the participant remains in hospital and by telehealth after discharge.houlder-specific movement will be assessed at each timepoint where feasible; if preoperative movement cannot be completed because of pain, this will be recorded.
Secondary outcome [6] 464858 0
Time from admission to the postoperative ward to first opioid request by patient
Timepoint [6] 464858 0
Within the first 24 postoperative hours.
Secondary outcome [7] 468674 0
Incidence of severe rebound pain within 24 hours after surgery.
Timepoint [7] 468674 0
Within first 24 postoperative hours
Secondary outcome [8] 468675 0
Worst pain experienced during the first 24 postoperative hours.
Timepoint [8] 468675 0
12 and 24 hours after surgery.
Secondary outcome [9] 468676 0
Participant-perceived duration of the analgesic effect of the nerve block.
Timepoint [9] 468676 0
Within first 24 postoperative hour
Secondary outcome [10] 468677 0
Participant-reported distress associated with temporary upper-limb motor block.
Timepoint [10] 468677 0
within first 24 hour postoperatively

Eligibility
Key inclusion criteria
Adults aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I–III undergoing elective unilateral shoulder arthroscopy, able to provide written informed consent and complete study questionnaires.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Contraindications to peripheral nerve block or local anaesthetic allergy; body mass index >45 kg/m²; pre-existing peripheral neuropathy or coagulation disorder; chronic pain or regular opioid use; significant systemic disease including moderate to severe pulmonary disease, chronic liver disease, congestive heart failure or renal impairment; known contralateral diaphragmatic dysfunction or previous phrenic nerve injury; impaired capacity to provide informed consent or complete study questionnaires; or emergency surgery.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed using sequentially numbered, opaque, sealed envelopes prepared in advance. Envelopes will be opened only after participant enrolment and written informed consent.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation sequence will be computer-generated using non-stratified permuted block randomisation implemented in Python (Python Software Foundation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
As a feasibility study, no formal sample size calculation based on statistical power was performed. A total sample of 40 participants (20 per group) was selected in accordance with published recommendations for pilot and feasibility trials. This sample is expected to provide sufficient precision to estimate key feasibility outcomes, including recruitment, intervention completion and follow-up rates, and to inform the design and sample size calculation of a future definitive randomised controlled trial.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 46141 0
3065 - Fitzroy

Funding & Sponsors
Funding source category [1] 322334 0
Charities/Societies/Foundations
Name [1] 322334 0
Australian New Zealand College of Anaesthetists
Country [1] 322334 0
Australia
Primary sponsor type
Hospital
Name
St. Vincent's Hospital Melbourne
Address
Country
Australia
Secondary sponsor category [1] 325251 0
University
Name [1] 325251 0
Department of Critical Care, University of Melbourne
Address [1] 325251 0
Country [1] 325251 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320837 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 320837 0
Ethics committee country [1] 320837 0
Australia
Date submitted for ethics approval [1] 320837 0
11/05/2026
Approval date [1] 320837 0
24/06/2026
Ethics approval number [1] 320837 0
2026/SVH01133

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151790 0
Dr Michelle Chong
Address 151790 0
Dr, Michelle Chong, Department of Anaesthesia and Pain Medicine, St. Vincent's Hospital, Melbourne, 41 Victoria Parade Fitzroy 3065
Country 151790 0
Australia
Phone 151790 0
+61392314253
Fax 151790 0
Email 151790 0
Contact person for public queries
Name 151791 0
Michelle Chong
Address 151791 0
Dr, Michelle Chong, Department of Anaesthesia and Pain Medicine, St. Vincent's Hospital, Melbourne, 41 Victoria Parade Fitzroy 3065
Country 151791 0
Australia
Phone 151791 0
+61392314253
Fax 151791 0
Email 151791 0
Contact person for scientific queries
Name 151792 0
Michelle Chong
Address 151792 0
Dr, Michelle Chong, Department of Anaesthesia and Pain Medicine, St. Vincent's Hospital, Melbourne, 41 Victoria Parade Fitzroy 3065
Country 151792 0
Australia
Phone 151792 0
+61392314253
Fax 151792 0
Email 151792 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Access to de-identified participant data will be considered following publication of the primary study results. Requests must be supported by a scientifically sound research proposal and will be reviewed by the study investigators. Approved requests may require a data sharing agreement and must comply with applicable ethics, privacy and institutional governance requirements.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.